-
-
7 . Periodical
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- 저자
- by Nash, Peter; Kirkham, Bruce; Okada, Masato; Rahman, Proton; Combe, Benard, et al.
- 소스
- The Lancet; June 2017, Vol. 389 Issue: 10086 p2317-2327, 11p